ALN-SNCA for Early Parkinson's Disease

This clinical trial is evaluating a new experimental drug called ALN-SNCA for people with early-stage Parkinson's disease, which affects movement due to nerve cell loss in the brain. The focus is on understanding whether this drug can be safely administered to patients by checking if it is tolerable and what potential side effects may occur. Parkinson's disease involves the harmful accumulation of a protein called α-synuclein, and this study is important because reducing this protein could potentially slow down the disease's progression, offering hope for more effective treatments in the future. Participants in the study receive the ALN-SNCA drug through an injection into the spinal fluid. Researchers monitor how the drug affects the levels of the α-synuclein protein in the cerebrospinal fluid, which surrounds the brain and spinal cord. They also measure how much of the drug is present in the blood, urine, and cerebrospinal fluid at different times to understand its distribution in the body. By doing this, the study aims to gather comprehensive data on the drug's safety and its potential effects on disease symptoms, paving the way for further research.